Matthew A Ciorba1, Christopher L Hallemeier, William F Stenson, Parag J Parikh. 1. aDivision of Gastroenterology, Washington University in St. Louis School of Medicine, St. Louis, Missouri bDepartment of Radiation Oncology, Mayo Clinic, Rochester, Minnesota cDepartment of Radiation Oncology, Washington University in St. Louis School of Medicine, St. Louis, Missouri, USA.
Abstract
PURPOSE OF REVIEW: There is currently an unmet need for agents that can prevent the gastrointestinal toxicity (mucositis and enteritis) associated with chemotherapy and radiation therapy of abdominal and pelvic cancers. Herein we provide an overview of how manipulation of the gut microbiota by probiotic administration affects these gastrointestinal symptoms. We focus this review on published human trials and also provide suggestions on how the field can move forward. RECENT FINDINGS: Several clinical trials of varying design, patient populations and probiotic products have been reported. Lactobacillus probiotics of adequate dosage demonstrate a potential to reduce gastrointestinal toxicity when administered prophylactically. Common study limitations prevent the widespread adoption of this practice at this point but are informative for rational design of future trials. SUMMARY: No single probiotic strain or product has emerged from human clinical trials for this indication. Further human studies are required to address limitations in the current literature. Preclinical model data should be used to inform the rational design of these new clinical trials to adequately address this important question.
PURPOSE OF REVIEW: There is currently an unmet need for agents that can prevent the gastrointestinal toxicity (mucositis and enteritis) associated with chemotherapy and radiation therapy of abdominal and pelvic cancers. Herein we provide an overview of how manipulation of the gut microbiota by probiotic administration affects these gastrointestinal symptoms. We focus this review on published human trials and also provide suggestions on how the field can move forward. RECENT FINDINGS: Several clinical trials of varying design, patient populations and probiotic products have been reported. Lactobacillus probiotics of adequate dosage demonstrate a potential to reduce gastrointestinal toxicity when administered prophylactically. Common study limitations prevent the widespread adoption of this practice at this point but are informative for rational design of future trials. SUMMARY: No single probiotic strain or product has emerged from human clinical trials for this indication. Further human studies are required to address limitations in the current literature. Preclinical model data should be used to inform the rational design of these new clinical trials to adequately address this important question.
Authors: P Delia; G Sansotta; V Donato; P Frosina; G Messina; C De Renzis; G Famularo Journal: World J Gastroenterol Date: 2007-02-14 Impact factor: 5.742
Authors: Lyudmila G Burdelya; Vadim I Krivokrysenko; Thomas C Tallant; Evguenia Strom; Anatoly S Gleiberman; Damodar Gupta; Oleg V Kurnasov; Farrel L Fort; Andrei L Osterman; Joseph A Didonato; Elena Feinstein; Andrei V Gudkov Journal: Science Date: 2008-04-11 Impact factor: 47.728
Authors: P Osterlund; T Ruotsalainen; R Korpela; M Saxelin; A Ollus; P Valta; M Kouri; I Elomaa; H Joensuu Journal: Br J Cancer Date: 2007-09-25 Impact factor: 7.640
Authors: R M Vasconcelos; N Sanfilippo; B J Paster; A R Kerr; Y Li; L Ramalho; E L Queiroz; B Smith; S T Sonis; P M Corby Journal: J Dent Res Date: 2016-04-06 Impact factor: 6.116
Authors: Terrence E Riehl; David Alvarado; Xueping Ee; Aaron Zuckerman; Lynn Foster; Vaishali Kapoor; Dinesh Thotala; Matthew A Ciorba; William F Stenson Journal: Gut Date: 2018-06-22 Impact factor: 23.059
Authors: Marika Cinausero; Giuseppe Aprile; Paola Ermacora; Debora Basile; Maria G Vitale; Valentina Fanotto; Giuseppe Parisi; Lorenzo Calvetti; Stephen T Sonis Journal: Front Pharmacol Date: 2017-06-08 Impact factor: 5.810